Developing recombinant and synthetic vaccines for the treatment of melanoma. - Wikidata - awgldk - TriplyDB

Developing recombinant and synthetic vaccines for the treatment of melanoma.

Developing recombinant and synthetic vaccines for the treatment of melanoma.

http://www.wikidata.org/entity/Q35946196

about

Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.DNA and RNA-based vaccines: principles, progress and prospects.The future of interleukin-2: enhancing therapeutic anticancer vaccines Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity Hierarchy, tolerance, and dominance in the antitumor T-cell response.Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.Calcaneal melanoma; our rare case and review of the literature.Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein.Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.Induction of in vivo resistance to Mycobacterium avium infection by intramuscular injection with DNA encoding interleukin-18.

P2860

Q30811481-0BC962D7-EA29-4A5E-8BA3-DF52A03BEC48 Q33783789-2311C4F1-4913-4645-B358-3135F733C0C6 Q33844221-701D8923-5877-4132-9753-740F10DAA41B Q34046869-9B9B8018-5670-47D9-8526-740C170A30BC Q34275036-D70DD5D0-D0A1-4CF0-A084-D28C28ADDA84 Q34276512-C6FFABF9-94A5-4FF0-BA9F-BC51B0FAF505 Q36432026-D15F9156-D173-48AE-8ABB-2AA8BFAA4CF6 Q36456716-B6401AD2-9B69-4A51-A8E8-22465CD50299 Q36509697-5A95E005-8617-41CA-90AD-34CF3FA44051 Q36648740-22DD3A60-47B0-4517-8EC5-A9C4A8FC7406 Q36946322-BB81D82F-A7DB-45E0-B3C6-95F1D19504A1 Q40813537-9B34EFA2-E49B-4CEF-BC17-E4AEAFEC7850 Q42673280-23243514-BDB4-4220-8163-146629E88441 Q54015727-7AFF4AF4-9C0F-49E8-986D-4666C81E3F02

P2860

Developing recombinant and synthetic vaccines for the treatment of melanoma.

http://www.wikidata.org/entity/Q35946196

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Developing recombinant and synthetic vaccines for the treatment of melanoma.

@ast

Developing recombinant and synthetic vaccines for the treatment of melanoma.

@en

type

label

Developing recombinant and synthetic vaccines for the treatment of melanoma.

@ast

Developing recombinant and synthetic vaccines for the treatment of melanoma.

@en

prefLabel

Developing recombinant and synthetic vaccines for the treatment of melanoma.

@ast

Developing recombinant and synthetic vaccines for the treatment of melanoma.

@en

P1433

Q35946196-1C6B10FE-E7B3-4428-9A7F-D583ABD758AF

P1476

Q35946196-26D4C2EA-AA3A-449F-A8DA-45A48B71B321

P2093

Q35946196-B82BDB9E-16B1-45C1-AF00-5B50E1A53FE3

P2860

Q35946196-03809098-809C-4473-8A2F-28B6F9B37A68

Q35946196-07AB7BB4-137C-4122-B435-3FDAB38E1429

Q35946196-0A356C92-39E8-46A3-9DE5-7358E90B6267

Q35946196-0D157521-5C59-4EAD-8A5E-F867A24B01B3

Q35946196-16783E63-E693-430F-8F2F-5DFFD88CFB2C

Q35946196-1E0D359C-0500-4BBA-A889-200551476D6D

Q35946196-20853BB7-0AAC-4B14-80F2-B1073C8D40C2

Q35946196-260664D9-A4B2-470D-9B06-3C94EEA02684

Q35946196-26432AFE-7737-4367-A2F2-F0DF5161D71F

Q35946196-28238435-0F0C-4909-A8CC-9C852515C495

P304

Q35946196-96FBA110-8C1C-46AC-BB09-65AC54B63679

P31

Q35946196-F0C45762-D0B1-4F78-9713-A0BC5CBE8253

P356

Q35946196-9BC92D1C-BFCA-48FF-85FA-8358A7ED73F2

P433

Q35946196-0E6FD836-72CB-425D-8564-99BDB12D2771

P478

Q35946196-AF024A1B-2254-499E-940A-B72B6BF5F5D9

P50

Q35946196-6D3E090D-982E-40D2-AC6D-0D658A1D3E39

P577

Q35946196-4A31D3AC-E97F-4EC9-BAC7-76926FC80FE3

P5875

Q35946196-793A7B61-E6A1-44C6-8798-595BDC761837

P698

Q35946196-89A48798-1ACF-4146-9652-A7F1338DC90B

P932

Q35946196-2BCB857A-35D8-4A06-9316-B9950F5D8B6E

P356

00001622-199901000-00012

P1433

Current Opinion in Oncology

P1476

Developing recombinant and synthetic vaccines for the treatment of melanoma

@en

P2093

S A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

Antigen processing in vivo and the elicitation of primary CTL responses

Identification of human cancers deficient in antigen processing

Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL

LAGE-1, a new gene with tumor specificity

Enhancement of antitumor immunity by CTLA-4 blockade

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.

P304

50-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00001622-199901000-00012

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

1999-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13374015

http://www.w3.org/2001/XMLSchema#string

P698

9914879

http://www.w3.org/2001/XMLSchema#string

P932

1950783

http://www.w3.org/2001/XMLSchema#string